A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 134 participants.

Also called NCT05536804

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 134 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05536804
  • EudraCT 2021-005273-47
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Austria, Canada, Denmark, Mexico, Netherlands (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05536804. Randomized; double masking; primary purpose treatment. Start 2023-02-08 (actual); primary completion 2026-07-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Acronym
TREASURE-CKD
Condition
Overweight
Condition
Obesity
Condition
T2D
Intervention (Drug)
Tirzepatide
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct05536804
Content hash
034880d0ed1c50f8505529b69853aeae5e52239aa108901e1265430b9bf14e2e